You are here

Article Text

Article menu
Download PDFPDF
DTB Select
MHRA drug safety update: risk of Fournier’s gangrene with SGLT2 inhibitors for diabetes

https://doi.org/10.1136/dtb.2019.000032

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Review of: Medical and Healthcare products Regulatory Agency. SGLT2 inhibitors: reports of Fournier’s gangrene. Drug Safety Update 2019;12(7):3.

    Key learning points

    • Necrotising fasciitis of the genitalia or perineum has been reported in people taking sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes.

    • If gangrene is suspected, treatment with SGLT2 inhibitors should be stopped and treatment for gangrene (including antibiotics and surgical debridement) started immediately.

    • Urogenital infection or perineal abscess may precede necrotising fasciitis.

    Prescribers and patients are …

    View Full Text

    Footnotes

    • Contributors DTB Team.

    • Provenance and peer review Commissioned; internally peer reviewed.